| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/40-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | GCP2; CKA-3; GCP-2; SCYB6 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CXCL6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CXCL6抗体的示例参考文献(内容为模拟示例，建议通过学术数据库核实具体文献)：
---
1. **文献名称**: *"CXCL6 Neutralizing Antibody Attenuates Inflammation and Fibrosis in Murine Lung Injury Models"*
**作者**: Zhang Y, et al.
**摘要**: 该研究开发了一种针对CXCL6的中和抗体，并在小鼠肺损伤模型中验证其效果。抗体通过抑制CXCL6与受体CXCR1/2的相互作用，显著减少中性粒细胞浸润和胶原沉积，表明其在治疗炎症性肺病中的潜在应用。
---
2. **文献名称**: *"Monoclonal Antibody Targeting CXCL6 Suppresses Tumor Angiogenesis and Metastasis in Colorectal Cancer"*
**作者**: Wang L, et al.
**摘要**: 研究团队制备了一种抗CXCL6的单克隆抗体，发现其能有效抑制结直肠癌模型中肿瘤血管生成和转移。机制研究表明，抗体通过阻断CXCL6介导的VEGF通路活化发挥作用。
---
3. **文献名称**: *"Development of a High-Affinity Anti-CXCL6 Antibody for Functional Studies in Autoimmune Arthritis"*
**作者**: Kim S, et al.
**摘要**: 本研究报道了一种高亲和力抗CXCL6抗体的开发，并在类风湿性关节炎模型中验证其功能。抗体可显著降低关节滑液中促炎细胞因子水平，提示其作为治疗自身免疫疾病的候选药物。
---
4. **文献名称**: *"CXCL6 Antibody-Based Therapeutic Strategy Reduces Neutrophil Recruitment in Sepsis"*
**作者**: Rodriguez A, et al.
**摘要**: 通过动物实验证明，抗CXCL6抗体能够减少脓毒症模型中的中性粒细胞过度募集，改善器官损伤和生存率，为脓毒症治疗提供了新方向。
---
**注意**：以上文献为示例，实际文献需通过PubMed、Google Scholar等平台检索关键词“CXCL6 antibody”或“CXCL6 neutralizing antibody”获取。
CXCL6 (C-X-C motif chemokine ligand 6), also known as granulocyte chemotactic protein-2 (GCP-2), is a small cytokine belonging to the CXC chemokine family. It plays a critical role in neutrophil chemotaxis, angiogenesis, and inflammation by interacting with its receptors, CXCR1 and CXCR2. CXCL6 is implicated in various pathological conditions, including chronic inflammatory diseases, cancer progression, and tissue repair.
CXCL6 antibodies are essential tools for detecting and analyzing the expression, localization, and function of CXCL6 in research. These antibodies enable techniques like Western blotting, immunohistochemistry (IHC), and ELISA, helping to elucidate CXCL6's role in disease mechanisms. For instance, elevated CXCL6 levels are linked to tumor aggressiveness in cancers such as colorectal and lung cancer, making its antibody valuable in oncology studies.
Commercially available CXCL6 antibodies are typically monoclonal or polyclonal, with specificity validated through knockout controls or neutralizing assays. Researchers also use neutralizing antibodies to block CXCL6-receptor interactions, exploring therapeutic potential in inflammatory disorders or cancer. However, challenges remain, including cross-reactivity with homologous chemokines (e.g., CXCL5) and variability in performance across experimental models.
Overall, CXCL6 antibodies serve as pivotal reagents in both basic research and drug development, advancing understanding of chemokine-mediated pathways and their clinical relevance.
×
